Page 107 - Sohini Das

India's first REIT is here: Embassy Office Parks proposes to raise Rs 52 bn

The joint venture of Blackstone and Embassy Group eyes Rs 52 bn through listing of 33 mn sq ft of office space

Oxytocin ban: Sole producer KAPL struggles with excess capacity, inventory

The firm had capacity to produce five million ampoules of oxytocin in a month; it is in the process of adding another 5.1 million ampoules a month of capacity by October 15, says MD Nirja Saraf

Shivinder Singh snaps ties with brother Malvinder, drags him to NCLT

Accuses Malvinder and Godhwani of oppression and mismanagement of group firms

J&J faulty hip implant case: Govt asks all states to form committees

The government has accepted the proposal but has decided to form state-level committees

Abbott India ups vaccines play, to launch products in infant segment

According to analysts, AIL's presence in the high-margin vaccine segment is likely to drive its future growth

After Fortis race, Manipal plots growth in India, overseas markets

Rough estimates show that at a rate of Rs 10 million per hospital bed, the investment in India alone would be around Rs 20 billion

Aurobindo pharma likely to clinch Mallinckrodt deal for $800 mn this July

Street is cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs

Indian companies giving MNCs a run for their money in vitamins

Three of top five pharmaceutical companies by market share based in India

Fortis Healthcare stake sale: Munjal-Burman seek level playing field

Hero Enterprise has criticised the Fortis Healthcare board's latest decision and has sought a level playing field for all the bidders

Rs 40-bn rights issue addresses concerns of Fortis shareholders: Ranjan Pai

Now there is also a plan to launch a Rs 40-billion rights issue for all shareholders after the demerger, which will help existing Fortis shareholders to participate, he added

Manipal sweetens offer for Fortis hospitals, proposes Rs 40-bn rights issue

Fortis Healthcare notified the stock exchange that it had received an unsolicited binding offer, which was under consideration

10 years of pharmaceutical sector: Controls, regulations stymie growth

It has also been a decade of major mergers and acquisitions, the most noteworthy one perhaps being the Sun Pharma-Ranbaxy deal

Olx betting on B2C segment to boost market share in used-car market

At present, OLX gets around 120,000 fresh unique B2C listing every month and 450,000 unique listings every month overall

Price crash ahead? Key diabetes, cancer drugs to go off-patent in India

The development is likely to trigger launch of generic versions by Indian drug majors; this would be a great relief to patients as prices might come down by 25% or so

How Eris is weaving a success story around its 4 distressed acquisitions

Eris Lifesciences started new neuro-psychiatry and women healthcare divisions for Strides portfolio and a new nutrition division for UTH portfolio

Danone's dairy tales: Why the French major gave up on India's market

Why did the French major give up on the world's largest dairy market and what does that mean for other brands in the fray?

GM raced ahead of peers, selling more vehicles as it exited India

In passenger cars, the firm even outpaced M&M by a huge margin; it has also consistently had a better market share than other foreign companies operating in India

Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share

Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these

Approval for generics drug up but US business shrinks for home firms

The trend is likely to continue for the next few quarters before the benefit from new drug launches start to accrue

Problem of plenty: Milk procurement hit, prices to dairy farmers drop 20%

A private dairy based in the NCR said the market was flush with SMP and prices had fallen to Rs 150 a kg or so in the domestic market, down by 30 per cent